Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-03-05 Capital/Financing Update
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
Capital/Financing Update Classification · 98% confidence The document is explicitly titled a "Press Release" announcing that Sanofi has "successfully priced its offering of EUR 1.5 billion of notes across 2 tranches." This describes a specific financing activity where the company is raising capital through debt issuance (bond issue). Reviewing the definitions, the 'Capital/Financing Update' (CAP) category is the most appropriate fit, as it covers 'Updates on company fundraising, financing activities, or capital structure changes.' It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific capital transaction.
2025-03-05 English
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires
Capital/Financing Update Classification · 99% confidence The document is a press release from Sanofi announcing the successful placement of 1.5 billion euros in bonds (obligations) in two tranches (variable and fixed rate). This action directly relates to the company raising capital or changing its financing structure. Based on the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific financing event.
2025-03-05 French
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' which translates to 'Declaration of transactions on own shares'. It details daily aggregated and individual transactions of Sanofi's own shares, including volume, price, dates, and market codes. The content is a detailed report of share buybacks or repurchases by the company, consistent with disclosures required under market abuse regulations (MAR). There is no indication that this is an announcement of a report or a certification; it is a direct declaration of transactions. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail support this classification with high confidence.
2025-03-03 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and details Sanofi's purchases of its own shares over a specific period (24 February 2025 to 28 February 2025). It includes aggregated daily volumes, prices, and broker transaction details. The content focuses exclusively on share repurchase activity, which aligns with reporting requirements for transactions in own shares. There is no indication of financial results, management commentary, or other report types. The document is substantive and not a brief announcement or certification. Therefore, the document fits the category of 'Transaction in Own Shares' (POS).
2025-03-03 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes references to press releases attached as exhibits, indicating it is a regulatory announcement rather than a full report. The document length is short (1491 characters), and it primarily serves to disclose recent press releases and corporate updates. There is no substantive financial data or detailed report content. According to the rules, such filings are best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-02-28 English
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and announces a specific regulatory event: the approval of the drug Sarclisa by the Ministry of Health, Labour and Welfare (MHLW) in Japan. It contains quotes from management, details about the drug's efficacy based on clinical studies (IMROZ phase 3), and standard boilerplate sections like 'About Sarclisa', media/investor contacts, and forward-looking statements typical of a corporate announcement. This format strongly indicates an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, timely announcement about a major business event (drug approval) rather than a comprehensive financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were quarterly results, but since it is a specific regulatory/business update, it falls under the general category of a significant announcement. Given the options, 'ER' is often used for major business updates outside of standard financial reporting periods, but 'RNS' (Regulatory Filings) is the most appropriate fallback for non-standard, material corporate news releases that aren't explicitly defined elsewhere. However, press releases announcing key business developments, especially those related to product milestones, are often categorized as Earnings Releases (ER) in databases when they are not tied to a specific quarterly filing, or sometimes as Regulatory Filings (RNS). Given the structure and content (announcing a major approval), it is a material corporate announcement. Since it is not a comprehensive financial report (10-K/IR) or a transcript (CT), and it is a formal press release, RNS is the safest general classification for material, non-financial-period-specific announcements, although ER is also plausible if the database uses it broadly for positive news. I will classify it as RNS as it is a general regulatory/material announcement.
2025-02-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.